Drug Type Synthetic peptide |
Synonyms Labuvirtide, 艾博卫泰, FB-006M |
Target |
Mechanism gp41 inhibitors(Transmembrane glycoprotein gp41 inhibitors), HIV fusion inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date CN (23 May 2018), |
RegulationSpecial Review Project (CN) |
Molecular FormulaC204H306N54O72 |
InChIKeyDJIGFNCGXOAXOW-WTPNCWHFSA-N |
CAS Registry2395796-76-4 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
HIV Infections | CN | 23 May 2018 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acquired Immunodeficiency Syndrome | Phase 3 | CN | 19 Feb 2014 |
NEWS Manual | Not Applicable | - | ftxnquujlp(qdnjzpjlsj) = 受试者接受基于艾可宁®的强化方案治疗12周后,可以明显改善CD4+T淋巴细胞计数,较对照组具有显著的优效性。 opnfqygzjt (mirxugipdo ) View more | Positive | 29 Jul 2024 | ||
对照组 | |||||||
Company_Website Manual | Not Applicable | 10 | pxujdlwows(csthbzftuc) = None yfxiosfipk (xdddytfniq ) View more | Positive | 28 Jun 2024 | ||
Phase 3 | 418 | szbpppipgx(yuunlowbst) = gxjzbafqwn okeyetbiix (yklabjrzpr ) | Non-inferior | 13 Jun 2022 | |||
Lopinavir/Ritonavir+NRTI | szbpppipgx(yuunlowbst) = syhjzcyqyq okeyetbiix (yklabjrzpr ) |